UK - Porton Capital portfolio company Acolyte Biomedica sold to 3M

Porton Capital has sold Acolyte Biomedica, a developer of technology to combat hospital acquired infections to 3M. Porton Capital first invested in Acolyte in 2004, participating in a ТЃ3.7m expansion round. In 2002, BioProjects International led a ТЃ2.6m investment in the pharmaceutial company. At the time of the exit, Porton Capital held close to 50% of the company.